INTRODUCTION
============

The circulating liver-derived protein proprotein convertase subtilisin/kexin type-9 (PCSK9) has emerged in the last decade as a major drug target in cardiovascular medicine. Landmark discoveries in human genetics formed a clear link between PCSK9 function and circulating levels of LDL-cholesterol (LDL-C), the major risk factor for coronary heart disease (CHD) \[[@R1]\]. First, missense mutations in *PCSK9*, later determined to confer a gain-of-function, were found to cause a rare form of autosomal dominant hypercholesterolemia \[[@R2]\]; second, loss-of-function *PCSK9* mutations identified at relatively high frequencies (2--4%) in certain ethnic populations were associated with lowered plasma LDL-C levels and significant protection from CHD \[[@R3],[@R4]\]. Mechanistic studies determined that PCSK9 binds to the LDL receptor (LDLR) and promotes its lysosomal degradation in cells \[[@R5]--[@R7]\]. The molecular mapping of the PCSK9-LDLR binding interface aided the development of therapeutic anti-PCSK9 monoclonal antibodies (mAbs) that effectively block this interaction at the cell surface \[[@R8],[@R9]\]. These treatments have provided for unprecedented lowering of plasma LDL-C (up to 70%) along with an excellent safety profile in ongoing clinical trials (reviewed in \[[@R10],[@R11]\]). Herein, I describe recent studies that are continuing to decipher important details of PCSK9 biology, with a focus on PCSK9\'s role in regulating hepatic LDLR levels.  
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PCSK9: A UNIQUE PROPROTEIN CONVERTASE
=====================================

PCSK9 is a soluble member of the mammalian proprotein convertase family of secretory serine endoproteases. PCSK9 is mainly synthesized and secreted from liver with lower levels of expression in intestine, kidney and brain \[[@R12]\]. Proprotein convertases are initially produced as zymogen precursors that undergo autocatalytic cleavage in the endoplasmic reticulum (ER) lumen, releasing an N-terminal prodomain segment that associates noncovalently with the catalytic or C-terminal domains and acts as a folding chaperone and catalytic site inhibitor \[[@R13]\]. The attached prodomain typically undergoes a secondary cleavage event to relieve its inhibitory effect; however, the prodomain of secreted PCSK9 remains intact and tightly bound in the catalytic site, rendering the mature enzyme catalytically inert \[[@R14]\]. Accordingly, PCSK9 acts as a molecular chaperone to direct LDLR degradation in cultured hepatic cells and mouse liver \[[@R15],[@R16]\]. Mechanistic studies have identified two separate routes of LDLR degradation induced by PCSK9 (Fig. [1](#F1){ref-type="fig"}). In an intracellular pathway, nascent PCSK9 can bind to the LDLR and direct it from the trans-Golgi to lysosomes for degradation \[[@R17]\]. Alternatively, secreted PCSK9 binds at the cell surface to the first epidermal growth factor-like repeat (EGF-A) of LDLR \[[@R5],[@R6]\]. Upon internalization, bound PCSK9 inhibits endocytic recycling of LDLR, resulting in lysosomal degradation of both proteins \[[@R18],[@R19]\]. Extensive LDL lowering in response to injectable mAb therapies that block the PCSK9 : EGF-A interaction at the cell surface support that the latter pathway exerts the largest influence on hepatic LDLR levels in humans \[[@R11]\]. The LDLR EGF-A domain interaction is a primary conduit for plasma PCSK9 clearance \[[@R16]\], highlighting reciprocal relationships between LDLR and PCSK9 that ultimately dictate steady-state plasma LDL-C levels \[[@R20]\].

![Regulation of PCSK9-mediated LDLR degradation by plasma apolipoprotein B100. Two pathways exist in hepatic cells for degradation of LDLR directed by PCSK9 (red arrows). PCSK9 can bind to LDLR in the luminal secretory compartment and target LDLR to lysosomes in vesicles emanating from the trans-Golgi. Alternatively, secreted PCSK9 can bind to LDLR on the cell surface and be internalized with LDLRs in endocytic vesicles. Unlike ligands LDL (apoB100) and VLDL (apoE) that release from the LDLR within acidic early endosomes, PCSK9 remains bound and prevents LDLR recycling to the cell surface, redirecting the receptor to lysosomes in which both PCSK9 and LDLR are degraded. Within the circulation PCSK9 can bind to apoB100 on LDL particles, but not to apoB100 on VLDL particles. The binding site on apoB100 may be unmasked by lipolysis of triglycerides on VLDL particles or other lipid modifications and conversion of VLDL to the short-lived IDL, which is further converted to LDL. IDL, intermediate density lipoprotein.](colip-25-387-g002){#F1}

COREGULATION OF PCSK9 AND LDL RECEPTOR EXPRESSION BY SREBP-2
============================================================

PCSK9 expression is mainly regulated at the transcriptional level by sterol regulatory element-binding protein-2 (SREBP-2), a membrane-bound transcription factor that regulates cholesterol homeostasis in cells \[[@R21],[@R22]\]. Two major SREBP isoforms expressed in mouse liver have partially overlapping but differential gene targets: SREBP-1c mainly regulates genes involved in fatty acid synthesis, whereas SREBP-2 regulates genes involved in cholesterol synthesis and uptake, including *Ldlr* and *Pcsk9*\[[@R23]\]. Proteolytic processing of SREBPs to active nuclear forms occurs in response to lowered cholesterol levels in ER membranes \[[@R24]\]. Both SREBP isoforms in rodent liver are suppressed by fasting and induced upon refeeding \[[@R23]\]. SREBP-2 activity returns to the baseline level in the fed state, whereas SREBP-1c is further stimulated several-fold at both the transcriptional and protein processing levels by insulin \[[@R23]\]. In healthy humans, plasma PCSK9 levels are decreased with fasting and increased postprandially, and display a diurnal rhythm that mirror markers of hepatic cholesterol synthesis \[[@R25],[@R26]\]. In one study, plasma PCSK9 levels declined approximately 60% over a 36-h fasting period, whereas LDL-C remained relatively steady \[[@R25]\]. These observations are consistent with a temporal role of PCSK9, perhaps linked to intestinal and hepatic lipoprotein production. Statins induce SREBP-2 activity by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, which in turn increases hepatic LDLR expression and plasma LDL-C clearance. However, increased PCSK9 expression under these same conditions could attenuate statin efficacy by promoting LDLR degradation \[[@R27]\]. Thus, PCSK9 represents a potent counter-mechanism programmed into the SREBP pathway to limit LDLR activity. In addition to LDL, hepatic LDLRs clear triglyceride-rich VLDL and remnant chylomicrons through binding to apoE, and thus can affect fuel transport to peripheral tissues. Hepatic LDLR also interacts with newly assembled apoB lipoproteins within the secretory pathway or at the cell surface, thereby increasing apoB degradation \[[@R28],[@R29]\]. Several studies have demonstrated that PCSK9 expression promotes apoB secretion in hepatic cells and mouse liver \[[@R30]--[@R32]\]. This may occur in part through a neutralizing effect on LDLR activity \[[@R30]\]. However, a recent study showed that adenoviral overexpression of PCSK9 increased apoB secretion in primary hepatocytes derived from *Ldlr-/-* mice, and identified a direct interaction between apoB100 and endogenous PCSK9 in HepG2 cells \[[@R32]\].

REGULATION OF PCSK9 EXPRESSION IN LIVER BY HEPATOCYTE NUCLEAR FACTOR 1α
=======================================================================

The *PCSK9* proximal promoter contains an SRE-1 motif for binding to SREBP-2, an Sp-1 site, and a binding site for hepatocyte nuclear factor-1α (HNF1α), a liver-enriched transcription factor that cooperates with SREBP-2 in the basal transcription of *PCSK9*\[[@R33]\]. Direct and indirect gene targets of HNF1α in liver are involved in cholesterol, bile acid and lipoprotein metabolism along with acute-phase responses, leading to the hypothesis that HNF1α forms a link between metabolic and inflammatory pathways underlying CHD \[[@R34]\]. The role of HNF1α in PCSK9 regulation was originally identified in studies of berberine, a natural compound that stimulates LDLR expression post-transcriptionally in HepG2 cells, in part by inhibiting transactivation of PCSK9 mRNA expression by HNF1α \[[@R33]\]. Induced HNF1α activity in livers of hyperlipidemic hamsters led to an unbalanced situation favoring PCSK9-mediated LDLR degradation and a net increase in plasma LDL-C in response to statins \[[@R35]\]. A recent study by Ai *et al.*\[[@R36]\] showed that PCSK9 mRNA was decreased approximately 60% in hyperinsulinemic ob/ob mice, a model of obesity-related type 2 diabetes (T2D). A detailed analysis identified that insulin stimulation of mammalian target of rapamycin complex 1 (mTORC1) initiated a signaling cascade resulting in nuclear exclusion of HNF1α and decreased *Pcsk9* transcription. Conversely, inhibition of hepatic mTORC1 signaling in mouse liver by rapamycin or insulin receptor knockdown stimulated PCSK9 expression and reduced LDLR levels \[[@R36]\]. Differential stimulation of PCSK9 expression relative to LDLR could contribute to hypercholesterolemia associated with the use of rapamycin as an immunosuppressive agent in organ transplantation. These findings also suggest that PCSK9 secretion is dependent on the degree of hepatic insulin resistance in T2D. In a model of 'selective' insulin resistance, insulin fails to suppress gluconeogenesis in liver, although pathways that stimulate SREBP-1c and lipogenesis remain insulin sensitive, including the mTORC1 signaling arm \[[@R37],[@R38]\]. Therefore, HNF1α-mediated *PCSK9* transcription could decrease in an mTORC1-dependent manner during the compensatory hyperinsulinemia associated with early-stage T2D, and increase as plasma insulin levels decline in later stages of T2D, or in situations of total hepatic insulin resistance. It remains to be determined whether mTORC1-mediated suppression of PCSK9 mRNA expression occurs acutely during the postprandial insulin response, or whether this effect is related to chronic stimuli in hyperinsulinemic states. Importantly, mTOR is a central regulator of cell growth \[[@R39]\], and also receives inputs from nutritional stimuli or cytokines that may affect the balance of hepatic PCSK9 and LDLR expression in physiological or pathological settings.

REGULATION OF CIRCULATING PCSK9 ACTIVITY
========================================

Fasting plasma PCSK9 levels in humans display a positive correlation with LDL-C and plasma triglyceride, but explained less than 8% of variance in LDL-C levels in a large study of more than 3500 participants \[[@R40]\]. Among various lipoprotein classes, plasma PCSK9 levels showed the strongest positive correlation with intermediate density lipoprotein \[[@R41]\], a short-lived intermediate in the conversion of liver-derived VLDL to LDL in the plasma compartment, mainly through hydrolysis of triglyceride by lipoprotein lipase for fatty acid transfer to peripheral tissues. Recent studies have shown that greater than 30% of PCSK9 in fasted normolipidemic human plasma is bound to LDL particles via a protein--protein interaction with apoB100 \[[@R20],[@R32],[@R42]^▪▪^\] (Fig. [1](#F1){ref-type="fig"}). PCSK9 does not bind to VLDL \[[@R42]^▪▪^\] and may bind to a site on circulating apoB100-containing lipoproteins that is unmasked by lipase activity and/or lipoprotein remodeling mediated by cholesteryl ester transfer protein (CETP), a plasma protein that facilitates the net transfer of triglyceride from apoB100-containing lipoproteins to HDL in exchange for cholesteryl ester. In cell culture studies, LDL inhibited the ability of PCSK9 to bind to cell surface LDLRs in a manner independent of the LDL-LDLR interaction \[[@R42]^▪▪^\]. LDL association does not sterically interfere with PCSK9 binding to the LDLR EGF-A domain \[[@R42]^▪▪^\], but otherwise the inhibitory mechanism remains undefined. Mapping studies identified an N-terminal region of the PCSK9 prodomain (aa 31--52) as being required for LDL association *in vitro*\[[@R42]^▪▪^\]. This region appears to act as a negative allosteric effector of LDLR binding \[[@R8],[@R43],[@R44]\]. Thus, one possibility is that binding to LDL-apoB100 stabilizes a native autoinhibited conformation of PCSK9. In addition to LDL binding, the LDLR-degrading activity of secreted PCSK9 is attenuated by proteolysis by proprotein convertase enzymes furin or PC5/6A that removes a portion of the catalytic domain required for LDLR binding \[[@R45],[@R46]\]. Cleavage of PCSK9 can occur within the secretory pathway or on the cell surface of cultured hepatocytes, and is diminished by gain-of-function *PCSK9* mutations (e.g., F216L) in humans \[[@R47]\]. Approximately 10--20% of PCSK9 in human plasma is furin-cleaved, whereas a majority of plasma PCSK9 is in a truncated form in mice \[[@R47]\] and rats (Lagace T, unpublished observations). These animals lack CETP and have very low plasma LDL levels, suggesting a possible connection between lipoprotein-mediated and protease-mediated mechanisms regulating secreted PCSK9 activity.

POTENTIAL ROLES OF PCSK9 IN REVERSE CHOLESTEROL TRANSPORT AND INNATE IMMUNITY
=============================================================================

PCSK9 function presumably evolved in a low nutrient environment with frequent and unpredictable episodes of fasting. Within this context, PCSK9 may have played an important role to promote fatty acid transport to peripheral tissues by limiting hepatic uptake of lipoproteins containing apoB and apoE. PCSK9 function may also relate to innate immunity, as plasma lipoproteins participate in host defense against bacterial infections through sequestration and clearance of microbial-derived lipids such as lipopolysaccharide (LPS) \[[@R48]\]. For instance, LPS-binding protein is an acute-phase protein that catalyzes the transfer of LPS into lipoproteins, and is predominantly associated with VLDL and LDL fractions in healthy humans \[[@R49]\]. LPS-induced inflammation in mice increased PCSK9 secretion \[[@R50]\] and this effect was inhibited by berberine, implicating HNF1α-mediated transcriptional regulation \[[@R51]\]. Hepatic LDLRs also function in a process termed reverse cholesterol transport (RCT), in which excess cholesterol from peripheral tissues is exported to preβ-HDL acceptors and transported through the plasma compartment back to the liver for eventual intestinal excretion \[[@R52],[@R53]\]. Downregulation of RCT occurs at several levels in the innate immune response \[[@R48]\]. Decreased cholesterol efflux from peripheral tissues results in cholesterol-enrichment of plasma membrane lipid rafts and improved function of Toll-like receptors (TLRs), the characteristic pattern recognition receptors in host antimicrobial defense \[[@R48]\]. In the case of macrophage foam cells, elevated free cholesterol induces TLR-mediated as well as TLR-independent proinflammatory pathways that accelerate the pathogenesis of CHD \[[@R54]\]. In the presence of CETP, hepatic LDLRs can participate directly in RCT \[[@R52]\]. It is predictable that PCSK9-mediated LDLR degradation would inhibit this potential antiatherogenic role of CETP concomitantly increasing plasma levels of acceptor apoB-containing lipoproteins, thereby enhancing proatherogenic CETP-mediated transfer of triglyceride and cholesteryl ester between plasma lipoprotein particles \[[@R52]\]. The negative effect of PCSK9 on RCT may not only be mediated by LDLR lowering in liver. Le May *et al.*\[[@R55]^▪▪^\] showed that PCSK9-mediated LDLR degradation in small intestine represses the delivery of LDL-C and HDL-C for trans-intestinal cholesterol excretion, a nonbiliary route of fecal neutral sterol loss that contributes approximately 30% of total sterol excretion in mice, or 60% upon liver X receptor activation \[[@R56]\]. An important future direction is to further delineate the roles of PCSK9 in liver and intestinal mechanisms of RCT. These processes may in turn affect enterohepatic signaling and feedback regulation of lipoprotein metabolism, bile acid homeostasis and secretion of liver-derived acute-phase proteins relevant to CHD pathogenesis.

DYSREGULATED PCSK9 FUNCTION IN HYPERCHOLESTEROLEMIA
===================================================

Feedback control of PCSK9 activity through binding to LDL-apoB100 could serve to monitor lipolysis and/or lipid transfer reactions involving apoB100-containing lipoproteins. However, under modern human dietary conditions, the major determinant of a regulatory pool of LDL-apoB100 is hepatic LDL particle clearance. In this circumstance, PCSK9 function counter-intuitively promotes an expanded LDL pool size that, together with an extended lifespan, reveals a modern role in CHD. At typical concentrations found in fasted normolipidemic human plasma, molecules of LDL-apoB100 outnumber PCSK9 by greater than 200-to-1. Therefore, PCSK9 would presumably not influence LDL clearance by a stoichiometric effect, as the vast majority of circulating LDL particles would not contain bound PCSK9. Rather, equilibrium binding to LDL could affect the level of free active PCSK9 in plasma that is available to bind to hepatic LDLRs (Fig. [2](#F2){ref-type="fig"}). The effect of this binding interaction on plasma LDL level is amplified as PCSK9 directs the degradation of an LDLR molecule that normally undergoes endocytic recycling 100 or more times before it is degraded in cells \[[@R57]\]. In conditions of lowered liver LDLR function, de-novo cholesterol synthesis is increased (via SREBP-2 activation) to compensate for decreased LDL-C uptake \[[@R58]\]. This situation results in a concomitant increase in PCSK9 secretion, as evidenced by elevated plasma PCSK9 levels in individuals with familial hypercholesterolemia \[[@R59]\]. Although elevated LDL in hypercholesterolemia may shift the equilibrium in favor of LDL-bound and inactive PCSK9, because of the relatively low binding affinity (*Kd*∼ 300 nM) \[[@R42]^▪▪^\] there would still be ample free PCSK9 to accelerate hepatic LDLR degradation (Fig. [2](#F2){ref-type="fig"}). Eventually, a steady state is reached in which hepatic cholesterol and PCSK9 production rates are in concert with LDLR-mediated PCSK9 clearance (with attendant LDLR destruction) and LDLR-mediated LDL-C uptake. In the context of a modern diet, this homeostatic balance is maintained at the expense of lowered hepatic LDLRs. In this model, therapeutic PCSK9 inhibitors are predicted to have the dual benefit of preventing PCSK9-mediated LDLR degradation while also decreasing PCSK9 secretion from liver due to increased uptake of LDL-C and subsequent reduction in SREBP-2 activity. A recent study showed that plasma PCSK9 was significantly decreased approximately 12% in male patients consuming an isogenic Mediterannean-style diet shown to lower plasma levels of LDL-C and lathosterol, a marker of hepatic cholesterol synthesis \[[@R60]\]. Although relatively modest, diet-related reductions in hepatic PCSK9 secretion could be amplified over the longer term given reciprocal relationships in the LDLR-PCSK9-LDL axis.

![Model of proprotein convertase subtilisin/kexin type-9 dysregulation under conditions of elevated plasma proprotein convertase subtilisin/kexin type-9 concentration. At low concentrations of plasma PCSK9 (top panel), such as may be present in a low nutrient environment, PCSK9 senses the conversion of VLDL to LDL in the plasma compartment through its ability to bind to LDL. When plasma LDL is low relative to hepatic VLDL production and PCSK9 secretion, the majority of circulating PCSK9 is in a free active form and directs hepatic LDLR degradation. As the LDL/VLDL ratio increases, and as plasma PCSK9 levels decline in fasting, a progressively higher percentage of plasma PCSK9 becomes LDL-bound and inactive, thereby promoting hepatic clearance of LDL. At high concentrations of plasma PCSK9 and LDL (lower panel) PCSK9 activity is less sensitive to the VLDL-to-LDL conversion, and the regulatory pool of LDL-apoB100 is mainly a function of hepatic LDL clearance. Due to a relatively low binding affinity to LDL (*Kd*∼ 300 nM) \[[@R42]^▪▪^\], negative feedback control of PCSK9 activity becomes dysregulated at high PCSK9 levels. Although a higher percentage of total plasma PCSK9 may bind to LDL under conditions of hypercholesterolemia, because of increased hepatic PCSK9 secretion there remains a large component of free and active PCSK9 in the circulation.](colip-25-387-g003){#F2}

CONCLUSION
==========

It is becoming clear that the reach of PCSK9 extends beyond circulating LDL-C. For instance, PCSK9 inhibition in clinical trials have shown added benefits of increasing plasma HDL-C levels when lowering lipoprotein(a) \[Lp(a)\], an LDL-like particle with proinflammatory properties identified as an independent risk factor of CHD \[[@R61],[@R62]^▪▪^\]. Interestingly, Lp(a) binds poorly to LDLR, and is not decreased in response to statin treatment. It remains to be determined whether this and other PCSK9-mediated effects reflect the wide-ranging influence of LDLR on lipid and lipoprotein metabolism, or alternative receptors targeted for PCSK9 binding and degradation \[[@R10]\]. PCSK9 inhibitors have had an excellent safety profile in clinical trials \[[@R63]^▪▪^,[@R64]\], and a recent study reported that a common loss-of-function *PCSK9* allele (R46L) was not associated with cognitive performance, functional status, or noncardiovascular clinical events in an elderly population \[[@R65]\]. Elevated plasma PCSK9 levels in modern humans may overwhelm primary mechanisms for feedback control of PCSK9 production and activity. If so, pharmacological lowering of PCSK9 activity promises to provide a well tolerated and effective corrective measure.
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